Hamilton and Aplex Bio announce co-marketing agreement to automate Hyperplex PCR Assay Kits
Collaboration delivers an automated, high-plex molecular testing workflow on Hamilton liquid handling workstations
2 Apr 2026
Hamilton and Aplex Bio have announced a co-marketing agreement to jointly promote an automated liquid handling solution for Aplex Bio’s Hyperplex PCR™ (hpPCR™) Assay Kits on Hamilton robotic platforms.
The collaboration enables highly automated detection and quantification of up to 100 molecular markers in a single well, combining exceptional specificity, ultra-sensitive performance, and scalable laboratory automation.
Molecular analysis is at a pivotal point, as conventional PCR workflows can become impractical or cost-prohibitive for high-throughput applications requiring broad genomic insight or precise quantification of numerous, difficult target sequences within a single sample.
While next-generation sequencing (NGS) excels at discovering novel genes and provides exceptional sequence specificity, ongoing reagent costs, service fees, training requirements, and turnaround times continue to limit accessibility for many laboratories.
To address these challenges, laboratories increasingly require automated molecular testing solutions that can reliably and rapidly detect multiple low-abundance targets at scale, integrate seamlessly into existing workflows, and avoid rising cost per sample as multiplexing and analytical breadth increase.
Hyperplex PCR is a molecular counting technology powered by Nanopixels™, padlock probes, and rolling circle amplification–based digital assays. Together, these technologies enable single-nucleotide resolution, ultra-high sensitivity, and high-plex capability, delivering same-day, precise quantification of up to 100 targets per well.
Combined with Hamilton’s expertise in laboratory automation and protocol optimization, the partnership enhances the scalability, reproducibility, and data integrity of the Hyperplex PCR platform.
“Hamilton strives to partner with global leaders in their respective fields, making Aplex Bio and its innovative technology a perfect fit,” said Roberto Fantozzi, Director Commercial Excellence “The partnership allows researchers fast access to a highly automated workflow that speeds up processing time and improves data integrity.”
“We are very pleased to partner with Hamilton, a global leader in automation,” said Umear Naseem, CEO of Aplex Bio. “Hyperplex PCR was built to integrate seamlessly with existing laboratory environments by being SBS-compatible, automation-ready, and deployable without new infrastructure. Integrating hpPCR with Hamilton’s systems extends this vision, enabling rapid scalability and providing laboratories with immediate access to high-precision, high-plex testing in a sample-to-answer workflow. This collaboration supports our broader vision of making comprehensive molecular measurement both accessible and routine across a wide range of applications.”